VKA Reversal and LVADs

Program Goals

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

Risks of LVAD Use

Case Study 72-Year-Old Man With a Minor Bleed

Management Considerations Minor Bleed With Supratherapeutic INR

Case Study (cont) Development of an Intermediate GI Bleed

Management Considerations (cont) Intermediate GI Bleed With LVAD

FFP vs PCC

Is There a Role for FFP in VKA Reversal in Patients With LVAD and Bleeding?

Types of PCCs

4-Factor PCC and Risk of Thrombosis in Continuous Flow LVAD

Reversing VKA With Vitamin K in Patients With LVAD

Case Study (cont) Development of a Critical Bleed (ICH)

Management Considerations (cont) Critical Bleed (ICH) With LVAD

Case Conclusion Preparation for Heart Transplant

Management Considerations (cont) Preparation for Heart Transplant

Summary

Abbreviations

Abbreviations (cont)